The International Centers for Precision Oncology Foundation and Melbourne-based PreMIT Pty Ltd  today announced their future collaboration to develop a global network of precision oncology centers and theranostics centers known. Through their joint efforts, both sides plan to scale access to precision radiomolecular oncology for cancer patients worldwide and foster research and industry partnerships.At its core, theranostics uses radiopharmaceuticals for both the diagnosis and treatment of various types of cancer. With theranostics still an emerging medical field, both ICPO and PreMIT see the need for an accelerated increase in the number of clinical centers that:

see the provision of precision medicine as their priority;
Employ physicians and clinical staff with an excellent knowledge base in the field of nuclear medicine and in the application of advanced imaging technology;
install the most modern imaging equipment available to provide the most accurate diagnoses;
use cutting-edge protocols to provide safe and effective treatment options for cancer patients, and
Facilitate the development of innovative and effective radiopharmaceuticals for diagnosis and treatment.
The ICPO and PreMIT have signed an agreement to establish new theranostics centers that will operate under these principles. Based on their extensive collective medical and scientific experience, together with their broad networks and together with regional development partners from all over the world, the ICPO and PreMIT will start their cooperation. The facilities are being developed for reference centers such as the Melbourne Theranostic Innovation Center (MTIC), PreMIT's flagship site, which will begin clinical services in mid-February 2023. Construction is nearing completion at the MTIC site with the Siemens Biograph Vision Quadra PET/CT system being moved into the building on January 14th. Both sides will define best practice solutions,

With the help of its MTIC location, PreMIT will contribute its experience in the planning, development and operation of theranostics centers as well as in the planning and implementation of educational offers. The ICPO Foundation will help create and control quality and certification standards through its knowledge sharing and global community platform, and use its international reach to encourage the creation of new centers.

The network of theranostics centers will help bridge the gap between research and improved patient access, while also facilitating the development of novel radiopharmaceuticals. The partnerships with leading companies and pioneering scientific institutions are already supporting the innovation dynamic in technology and education in the field of precision radiomolecular oncology.

Oliver Buck, Trustee of the ICPO Foundation, stated, “We are delighted to join forces with PreMIT and Professor Rodney Hicks, who has been at the forefront of theranostics and precision oncology for more than 30 years. As a key thought leader in nuclear medicine and oncology worldwide, Professor Hicks has unparalleled credentials and the academic and industry connections to advance the development of new theranostics paradigms and bring outstanding value to ICPO theranostics center networks. We cannot think of a better partner to now pave the way for this significant step toward democratizing and scaling patient access to precision radiomolecular oncology globally.”

"We are very excited to be collaborating with the ICPO Foundation to accelerate the implementation of a shared vision to address the unmet needs of cancer patients in the clinical practice and make innovative theranostic methods accessible to all," added Professor Rodney Hicks, PreMIT Founder , Chairman and Chief Medical Officer. "We are confident that the international ICPO community of medical and industry experts and investors will successfully initiate the establishment of new theranostics centers of high added value for cancer patients worldwide."

-End-

The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. Therefore, compare translations with the original language version of the publication.

Contacts
PreMIT Media Contact
Chris Nolan
Principle Media Group
Email: info@mtic.net.au
Tel: +61 3 8373
7666 www.mtic.net.au

Contact person at the ICPO Foundation for media representatives
Nicola Scharrer
Community & Communication Officer
Email: Nicola.Scharrer@icpo.foundation
Tel: + 49 611 341 486 30
www.icpo.foundation

 

Source:businesswire.com

Report Abuse